Price to Sales (P/S)
since 2012
Calculation
AbbVie Inc., P/S, long-term trends, calculation
| P/S | = | Share price1, 2, 3 | ÷ | Sales per share1 | Sales per share1 | = | Net revenues1 (in millions) |
÷ | No. shares of common stock outstanding2 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 20, 2024 | 5.72 | = | 175.75 | ÷ | 30.75 | 30.75 | = | 54,318 | ÷ | 1,766,473,359 | |
| Feb 17, 2023 | 4.61 | = | 151.31 | ÷ | 32.81 | 32.81 | = | 58,054 | ÷ | 1,769,399,971 | |
| Feb 18, 2022 | 4.53 | = | 144.03 | ÷ | 31.77 | 31.77 | = | 56,197 | ÷ | 1,768,753,829 | |
| Feb 19, 2021 | 4.05 | = | 105.01 | ÷ | 25.94 | 25.94 | = | 45,804 | ÷ | 1,765,881,690 | |
| Feb 21, 2020 | 4.22 | = | 94.96 | ÷ | 22.49 | 22.49 | = | 33,266 | ÷ | 1,479,156,683 | |
| Feb 27, 2019 | 3.58 | = | 79.41 | ÷ | 22.20 | 22.20 | = | 32,753 | ÷ | 1,475,083,514 | |
| Feb 16, 2018 | 6.67 | = | 118.60 | ÷ | 17.77 | 17.77 | = | 28,216 | ÷ | 1,587,972,655 | |
| Feb 17, 2017 | 3.84 | = | 61.77 | ÷ | 16.08 | 16.08 | = | 25,638 | ÷ | 1,593,920,285 | |
| Feb 19, 2016 | 3.83 | = | 54.29 | ÷ | 14.19 | 14.19 | = | 22,859 | ÷ | 1,611,238,226 | |
| Feb 20, 2015 | 4.90 | = | 61.30 | ÷ | 12.52 | 12.52 | = | 19,960 | ÷ | 1,593,886,909 | |
| Feb 21, 2014 | 4.31 | = | 51.04 | ÷ | 11.83 | 11.83 | = | 18,790 | ÷ | 1,588,518,764 | |
| Mar 15, 2013 | 3.30 | = | 38.50 | ÷ | 11.65 | 11.65 | = | 18,380 | ÷ | 1,577,334,090 |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31).
1 US$
2 Data adjusted for splits and stock dividends.
3 Closing price as at the filing date of AbbVie Inc. Annual Report.
Comparison to Competitors
AbbVie Inc., P/S, long-term trends, comparison to competitors
| AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Moderna Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 20, 2024 | 5.72 | 5.78 | 2.19 | 7.76 | 20.77 | 3.40 | 4.43 | 5.43 | 5.52 | 2.66 | 7.84 | 4.99 |
| Feb 17, 2023 | 4.61 | 5.17 | 3.29 | 5.79 | 10.96 | 3.86 | 4.34 | 4.71 | 2.92 | 2.37 | 7.01 | 4.73 |
| Feb 18, 2022 | 4.53 | 5.10 | 3.16 | 6.37 | 8.01 | 2.85 | 4.66 | 3.96 | 3.45 | 3.18 | 4.20 | 5.39 |
| Feb 19, 2021 | 4.05 | 5.64 | 3.16 | 7.01 | 8.06 | 3.24 | 5.15 | 3.93 | 309.64 | 4.50 | 6.24 | 5.52 |
| Feb 21, 2020 | 4.22 | 6.03 | 5.52 | 6.29 | 6.03 | 4.00 | 4.79 | 4.33 | — | 3.66 | 5.34 | 4.83 |
| Feb 27, 2019 | 3.58 | 5.22 | 3.67 | 3.97 | 5.15 | 3.84 | 4.45 | 4.92 | — | 4.49 | 6.62 | 4.24 |
| Feb 16, 2018 | 6.67 | 5.82 | 5.02 | 3.70 | 3.71 | 4.10 | 4.56 | 3.68 | — | 4.05 | 5.92 | 4.01 |
| Feb 17, 2017 | 3.84 | 5.65 | 4.72 | 3.48 | 4.18 | 3.08 | 4.62 | 4.54 | — | 3.84 | 7.86 | 3.37 |
| Feb 19, 2016 | 3.83 | 5.28 | 6.07 | 2.91 | 4.02 | 3.80 | 4.13 | 3.56 | — | 3.76 | 9.38 | 3.05 |
| Feb 20, 2015 | 4.90 | 6.13 | 6.28 | 3.09 | 4.03 | 6.36 | 3.77 | 3.93 | — | 4.24 | 14.62 | 3.06 |
| Feb 21, 2014 | 4.31 | 5.22 | 5.48 | 2.78 | 2.81 | 11.95 | 3.63 | 3.78 | — | 3.97 | 15.52 | 3.74 |
| Mar 15, 2013 | 3.30 | 4.09 | 3.40 | 2.32 | 2.71 | 6.95 | 3.17 | 2.73 | — | 3.34 | 11.66 | 2.12 |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
AbbVie Inc., P/S, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
| AbbVie Inc. | Pharmaceuticals, Biotechnology & Life Sciences | |
|---|---|---|
| Feb 20, 2024 | 5.72 | 5.78 |
| Feb 17, 2023 | 4.61 | 4.44 |
| Feb 18, 2022 | 4.53 | 4.42 |
| Feb 19, 2021 | 4.05 | 5.00 |
| Feb 21, 2020 | 4.22 | 4.79 |
| Feb 27, 2019 | 3.58 | 4.46 |
| Feb 16, 2018 | 6.67 | 4.51 |
| Feb 17, 2017 | 3.84 | 4.24 |
| Feb 19, 2016 | 3.83 | 4.05 |
| Feb 20, 2015 | 4.90 | 4.46 |
| Feb 21, 2014 | 4.31 | 4.25 |
| Mar 15, 2013 | 3.30 | 3.24 |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31).
Comparison to Industry (Health Care)
AbbVie Inc., P/S, long-term trends, comparison to industry (health care)
| AbbVie Inc. | Health Care | |
|---|---|---|
| Feb 20, 2024 | 5.72 | 2.30 |
| Feb 17, 2023 | 4.61 | 33,191.58 |
| Feb 18, 2022 | 4.53 | 2.28 |
| Feb 19, 2021 | 4.05 | 2.25 |
| Feb 21, 2020 | 4.22 | 2.13 |
| Feb 27, 2019 | 3.58 | 2.33 |
| Feb 16, 2018 | 6.67 | 2.30 |
| Feb 17, 2017 | 3.84 | 2.12 |
| Feb 19, 2016 | 3.83 | 2.10 |
| Feb 20, 2015 | 4.90 | 2.38 |
| Feb 21, 2014 | 4.31 | 2.17 |
| Mar 15, 2013 | 3.30 | 1.73 |
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31).